Proteome and Phosphoproteome Analysis in TNF Long Term-Exposed Primary Human Monocytes.
CCAAT-Enhancer-Binding Protein-beta
/ metabolism
Glycogen Synthase Kinase 3
/ metabolism
HeLa Cells
Humans
Inflammation
/ metabolism
Monocytes
/ metabolism
NF-kappa B
/ metabolism
Phosphorylation
/ physiology
Proteome
/ metabolism
Signal Transduction
/ physiology
THP-1 Cells
Tumor Necrosis Factor-alpha
/ metabolism
NF-κB
TNF long term exposure
monocytes
phosphoproteomics
proteomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Mar 2019
12 Mar 2019
Historique:
received:
11
02
2019
revised:
27
02
2019
accepted:
06
03
2019
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
27
6
2019
Statut:
epublish
Résumé
To better understand the inflammation-associated mechanisms modulating and terminating tumor necrosis factor (TNF-)induced signal transduction and the development of TNF tolerance, we analyzed both the proteome and the phosphoproteome in TNF long term-incubated (i.e., 48 h) primary human monocytes using liquid chromatography-mass spectrometry. Our analyses revealed the presence of a defined set of proteins characterized by reproducible changes in expression and phosphorylation patterns in long term TNF-treated samples. In total, 148 proteins and 569 phosphopeptides were significantly regulated (103 proteins increased, 45 proteins decreased; 377 peptides with increased and 192 peptides with decreased phosphorylation). A variety of these proteins are associated with the non-canonical nuclear factor κB (NF-κB) pathway (nuclear factor κB (NFKB) 2, v-rel reticuloendotheliosis viral oncogene homolog (REL) B, indolamin-2,3-dioxygenase (IDO), kynureninase (KYNU)) or involved in the negative regulation of the canonical NF-κB system. Within the phosphopeptides, binding motifs for specific kinases were identified. Glycogen synthase kinase (GSK) 3 proved to be a promising candidate, since it targets NF-κB inhibiting factors, such as CCAAT/enhancer binding protein (C/EBP) β. Our experiments demonstrate that both proteome and phosphoproteome analysis can be effectively applied to study protein/phosphorylation patterns of primary monocytes. These results provide new regulatory candidates and evidence for a complex network of specific but synergistically acting/cooperating mechanisms enabling the affected cells to resist sustained TNF exposure and resulting in the resolution of inflammation.
Identifiants
pubmed: 30871024
pii: ijms20051241
doi: 10.3390/ijms20051241
pmc: PMC6429050
pii:
doi:
Substances chimiques
CCAAT-Enhancer-Binding Protein-beta
0
NF-kappa B
0
Proteome
0
Tumor Necrosis Factor-alpha
0
Glycogen Synthase Kinase 3
EC 2.7.11.26
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB566/B17
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2012/14
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2017/19
Organisme : Stiftung für Pathobiochemie und Molekulare Diagnostik
ID : 2018/19
Références
J Biol Chem. 2001 Jun 1;276(22):19664-71
pubmed: 11278638
J Leukoc Biol. 2001 Nov;70(5):821-9
pubmed: 11698503
Biochem J. 2004 Jan 1;377(Pt 1):249-55
pubmed: 14570592
Mol Cell Biol. 2004 Oct;24(19):8671-80
pubmed: 15367685
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9766-71
pubmed: 15985551
Clin Exp Immunol. 2005 Dec;142(3):481-9
pubmed: 16297160
J Immunol. 2006 Jul 1;177(1):665-72
pubmed: 16785565
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18619-24
pubmed: 18003900
Nat Rev Immunol. 2008 Nov;8(11):837-48
pubmed: 18927578
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Sci Signal. 2009 Feb 24;2(59):ra8
pubmed: 19244213
Cancer Res. 2009 Jun 15;69(12):4983-91
pubmed: 19491262
Cell Signal. 2009 Dec;21(12):1918-24
pubmed: 19733238
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
Br J Haematol. 2010 Mar;148(5):777-90
pubmed: 19958352
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Nat Immunol. 2011 May 22;12(7):607-15
pubmed: 21602809
Int J Alzheimers Dis. 2011;2011:505607
pubmed: 21629754
Nat Immunol. 2011 Jul 31;12(9):870-8
pubmed: 21804557
Curr Opin Immunol. 2011 Oct;23(5):613-9
pubmed: 21852080
Cell Signal. 2012 Jun;24(6):1287-96
pubmed: 22374303
Curr Pharm Des. 2012;18(13):1730-50
pubmed: 22397328
Aging Cell. 2012 Aug;11(4):617-27
pubmed: 22510478
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Nat Rev Immunol. 2013 Jan;13(1):59-66
pubmed: 23197111
Nat Rev Drug Discov. 2013 Jan;12(1):64-82
pubmed: 23237916
Carcinogenesis. 2013 Sep;34(9):1943-54
pubmed: 23671130
PLoS One. 2013 Sep 02;8(9):e73153
pubmed: 24023826
J Immunol. 2014 Apr 1;192(7):3143-55
pubmed: 24574500
Front Biosci (Landmark Ed). 2015 Jun 01;20:1116-43
pubmed: 25961549
Nat Commun. 2015 Sep 16;6:8272
pubmed: 26374165
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
PLoS One. 2015 Dec 08;10(12):e0144338
pubmed: 26646662
J Amino Acids. 2015;2015:973548
pubmed: 26881062
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Proteomics Clin Appl. 2017 Mar;11(3-4):
pubmed: 27860399
Cell Death Differ. 2017 Jul;24(7):1172-1183
pubmed: 28362430
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
Cell Signal. 2017 Sep;37:123-135
pubmed: 28629782
Expert Rev Proteomics. 2017 Sep;14(9):825-839
pubmed: 28780899
J Immunol Res. 2017;2017:9570129
pubmed: 29250561
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212